收稿日期: 2024-04-08
录用日期: 2024-10-08
网络出版日期: 2025-02-25
A single-center retrospective clinical study of 7 cases of acquired hemophilia A
Received date: 2024-04-08
Accepted date: 2024-10-08
Online published: 2025-02-25
目的:探讨获得性血友病A(Acquired hemophilia A,AHA)的病因、临床表现、诊治及预后,提高临床对AHA的认识及诊治水平。方法:对我院2013年1月至2023年12月诊断的7例AHA患者的进行回顾性分析,并分别以“Acquired hemophilia A”及“获得性血友病A”在PubMed及中国知网、万方数据库中检索相关文献,从一般资料、病因、诊断时间、临床表现、治疗及预后方面进行对比分析。结果:7例AHA患者均为女性,中位年龄为44.1岁(26~68岁),1例继发于乙型病毒性肝炎感染,1例继发于妊娠,1例为消化道手术后发病,1例继发于干燥综合征。皮肤瘀斑是AHA患者最主要临床表现(7/7),且均有活化部分凝血活酶时间(activated partial thromboplastin time, APTT)升高、凝血因子Ⅷ(factor Ⅷ, FⅧ)活性(FⅧ:C)降低、FⅧ抗体(FⅧ:Ab)升高。有6例患者接受止血治疗,所有患者接受清除抗体治疗。本组中位随访391 d(28~777 d),除1例患者失访,4例患者达到完全缓解(complete response, CR),达到CR的中位时间为40 d(27~48 d),1例患者达到部分缓解(partial response, PR),均未出现复发。1例患者治疗无效(no response, NR),在随访期间无新发临床出血表现。文献检索到1252例,AHA男女均可发病,男女比例为1.18:1,男女中位年龄分别为65.6岁、55.8岁。56.8% AHA患者为特发型,11.4%与肿瘤、11.1%与自身免疫性疾病、6.7%与妊娠等相关。55%患者接受旁路途径药物是止血治疗,清除抗体治疗多采用以糖皮质激素、环磷酰胺及利妥昔单抗为基础的方案。结论:AHA可继发于肿瘤、自身免疫性疾病、感染、妊娠等,患者多有皮肤淤斑;旁路途径止血、免疫抑制治疗清除抗体,多数患者预后良好。
钱玲玲 , 裴孝平 , 孙爱红 , 何斌 , 孙梅 . 单中心7例获得性血友病A的回顾性临床研究[J]. 诊断学理论与实践, 2024 , 23(05) : 524 -530 . DOI: 10.16150/j.1671-2870.2024.05.009
Objective This study aims to explore the etiology, clinical manifestations, diagnosis and treatment, and prognosis of acquired hemophilia A (AHA), and to improve the clinical understanding, diagnosis, and treatment of AHA. Methods A retrospective analysis was conducted on 7 cases of AHA diagnosed at our hospital from January 2013 to December 2023. Relevant literature was searched in PubMed, CNKI, and Wanfang databases using the terms “Acquired hemophilia A”. A comparative analysis was performed on general data, etiology, diagnosis time, clinical manifestations, treatment, and prognosis. Results All 7 AHA patients were female, with a median age of 44.1 years (range 26-68 years). One case was secondary to hepatitis B virus infection; one was secondary to pregnancy; one developed after gastrointestinal surgery; and one was secondary to Sjögren’s syndrome. Skin ecchymosis was the most common clinical manifestation of AHA(7/7), with increased activated partial thromboplastin time (APTT), decreased coagulation factor Ⅷ(FⅧ) activity (FⅧ:C), and increased FⅧ antibody (FⅧ: Ab). Six patients received hemostatic therapy, and all patients received antibody clearance therapy. The median follow-up time was 391 days (28-777 days), with one patient lost to follow-up. Four patients achieved complete response (CR), with a median time to CR of 40 days (27-48 days). One patient achieved partial response (PR), and no recurrence occurred. One patient had no response (NR) and no new clinical bleeding during the follow-up period. The literature review found that AHA can occur in both men and women, with a predominance of women of childbearing age. 56.8% of the patients had idiopathic AHA, while 11.4%, 11.1%, and 6.7% patients of AHA associated with tumors, autoimmune diseases, and pregnancy, respectively. The male to female ratio is 1.18:1, with median ages of 65.6 years and 55.8 years, respectively. Bypass pathway drugs were the first choice for hemostatic treatment, and antibody clearance therapy was mostly based on glucocorticoids, cyclophosphamide, and rituximab. Conclusions AHA can be secondary to tumors, autoimmune diseases, infections, pregnancy, etc. Patients may have skin bruising; The use of bypass routes for hemostasis and immunosuppressive therapy to clear antibodies results in a good prognosis for most patients.
Key words: Acquired hemophilia A; Diagnosis; Treatment
[1] | COLLINS P W, HIRSCH S, BAGLIN T P, et al. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation[J]. Blood, 2007, 109(5):1870-1877. |
[2] | TIEDE A, WAHLER S. The rising incidence of acquired haemophilia A in Germany[J]. Haemophilia, 2021, 27(4):e466-e468. |
[3] | PAI M. Acquired Hemophilia A[J]. Hematol Oncol Clin North Am, 2021, 35(6):1131-1142. |
[4] | DELGADO J, JIMENEZ-YUSTE V, HERNANDEZ-NAVARRO F, et al. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors[J]. Br J Haematol, 2003, 121(1):21-35. |
[5] | BAUDO F, COLLINS P, HUTH-KüHNE A, et al. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry[J]. Blood, 2012, 120(1):39-46. |
[6] | KNOEBL P, MARCO P, BAUDO F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)[J]. J Thromb Haemost, 2012, 10(4):622-631. |
[7] | SUN B, XUE F, FENG Y, et al. Outcome of CARE: a 6-year national registry of acquired haemophilia A in China[J]. Br J Haematol, 2019, 187(5):653-665. |
[8] | 陈桂芳, 何芸, 刘叶, 等. 22例获得性血友病A患者的临床特点及预后[J]. 贵州医科大学学报, 2024, 49(8):1218-1223,1229. |
CHEN G F, HE Y, LIU Y, et al. Clinical features and prognosis of 22 patients with acquired hemophilia A[J]. J Guizhou Med Univ, 2024, 49(8):1218-1223,1229. | |
[9] | KAHLE J, ORLOWSKI A, STICHEL D, et al. Frequency and epitope specificity of anti-factor Ⅷ C1 domain antibodies in acquired and congenital hemophilia A[J]. Blood, 2017, 130(6):808-816. |
[10] | TIEDE A, HOFBAUER C J, WERWITZKE S, et al. Anti-factor Ⅷ IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study[J]. Blood, 2016, 127(19):2289-2297. |
[11] | TENGBORN L, BAUDO F, HUTH-KüHNE A, et al. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry[J]. BJOG, 2012, 119(12):1529-1537. |
[12] | KHAN U Z, YANG X, MASROOR M, et al. Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature[J]. BMC Surg, 2020, 20(1):213. |
[13] | 刘凌, 冯莹, 谢玮, 等. 44例获得性血友病A的病因、临床表现及诊疗的探讨[J]. 血栓与止血学, 2018, 24(1):1-4. |
LIU L, FENG Y, XIE W, et al. The etiology, clinical manifestation,diagnosis and treatment effect in patients with acquired hemophilia-A[J]. Chin J Thromb Hemost, 2018, 24(1):1-4. | |
[14] | 周莉, 张馨慧, 冯尚龙, 等. rFⅦa联合强化免疫抑制治疗获得性血友病A的回顾性临床研究[J]. 血栓与止血学, 2021, 27(2):181-185. |
ZHOU L, ZHANG X H, FENG S L, et al. A retrospective clinical study of rFⅦa combined with immunosuppressive therapy in the treatment of acquired hemophilia A[J]. Chin J Thromb Hemost, 2021, 27(2):181-185. | |
[15] | 中华医学会血液学分会血栓与止血学组, 中国血友病协作组. 获得性血友病A诊断与治疗中国指南(2021年版)[J]. 中华血液学杂志, 2021, 42(10):793-799. |
Thrombosis and Hemostasis Group, Chinese Society of Hematology, Chinese Medical Association; Hemophilia Treatment Center Collaborative Network of China. Chinese guidelines on the diagnosis and treatment of acquired hemophilia A (2021)[J]. Chin J Hematol, 2021, 42(10):793-799. | |
[16] | TIEDE A, COLLINS P, KNOEBL P, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A[J]. Haematologica, 2020, 105(7):1791-1801. |
[17] | KRUSE-JARRES R, KEMPTON CL, BAUDO F, et al. Acquired hemophilia A: updated review of evidence and treatment guidance[J]. Am J Hematol, 2017, 92(7):695-705. |
[18] | TIEDE A, KLAMROTH R, SCHARF R E, et al. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study[J]. Blood, 2015, 125(7):1091-1097. |
[19] | HOLSTEIN K, LIU X, SMITH A, et al. Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study[J]. Blood, 2020, 136(3):279-287. |
[20] | SHIMA M, AMANO K, OGAWA Y, et al. A prospective, multicenter, open-label phase Ⅲ study of emicizumab prophylaxis in patients with acquired hemophilia A[J]. J Thromb Haemost, 2023, 21(3):534-545. |
[21] | TIEDE A, HART C, KN?BL P, et al. Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study[J]. Lancet Haematol, 2023, 10(11):e913-e921. |
[22] | OLDENBURG J, MAHLANGU J N, KIM B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors[J]. N Engl J Med, 2017, 377(9):809-818. |
[23] | COLLINS P, BAUDO F, KNOEBL P, et al. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)[J]. Blood, 2012, 120(1):47-55. |
[24] | 郭玉洁, 韩欢, 李笑, 等. 单中心25例获得性血友病A临床分析[J]. 中国实验血液学杂志, 2024, 32(6):1829-1833. |
GUO Y J, HAN H, LI X, et al. Clinical analysis of 25 cases of acquired hemophilia A in a single center[J]. J Exp Hematol, 2024, 32(6):1829-1833. | |
[25] | LIU W, LIU J, XUE F, et al. Anti-CD38 antibody for refractory acquired hemophilia A[J]. J Thromb Haemost, 2023, 21(6):1515-1518. |
/
〈 |
|
〉 |